Brief: Veracyte Says Co's Decipher Bladder Test Accurately Identifies Tumors Most Likely To Respond To Chemotherapy
13/10/2021 14:43
Oct 13 (Reuters) - Veracyte Inc VCYT.O :
* NEW PUBLICATION DEMONSTRATES ABILITY OF VERACYTE’S
DECIPHER
BLADDER TEST TO IDENTIFY TUMORS MOST LIKELY TO RESPOND TO
CHEMOTHERAPY
Source text for Eikon: ID:nBw87STJBa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina